Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine

Inclusion Criteria: * Subjects aged 2 months, 6-11 months, 1-5 years, and 18-59 years at the time of screening * Informed consent is obtained from the subject and the subject and/or guardian (attorney-in-fact) is able to sign the informed consent form * Subjects are able and willing to comply with the requirements of the clinical trial protocol and are able to complete the full study follow up Exclusion criteria for first dose: * 2 months old, 6 months old \~ 5 years old people have been vaccinated with Hib-containing vaccines * 2-month-old, 6\~11-month-old infants who were born prematurely (delivered before the 37th week of gestation), low birth weight (birth weight \<2500g) * 2-month-old, 6\~11-month-old infants with abnormal labor and delivery, history of asphyxia rescue, history of neurological damage * Those with history of Haemophilus influenzae type b infection * Those with history of epilepsy, convulsions, convulsions, cerebral palsy, or history of psychiatric illness or family history or other progressive neurological diseases * Have been diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), juvenile rheumatoid arthritis (JRA), or other autoimmune diseases * History of allergy to vaccines or vaccine components, severe side effects to vaccines such as urticaria, dyspnea, angioneurotic edema * Female with positive urine pregnancy test or breastfeeding subjects, subjects or their partners with pregnancy plan within 6 months (only for 18\~59 years old) * Fever with axillary temperature \> 37.0°C * Known or suspected to be suffering from acute diseases or serious chronic diseases (including: serious respiratory diseases, serious cardiovascular diseases, liver and kidney diseases, serious skin diseases, malignant tumors, tuberculosis, etc.); or in the acute exacerbation of chronic diseases * Those who have hypertension that cannot be controlled by medication (at the time of on-site measurement: systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥100 mmHg) (only applicable to 18\~59 years old) * Any of the routine blood biochemistry indexes during the screening period judged to be clinically significant by the investigator (only applicable to 2\~5, 18\~59 years old) * Have no spleen or functional absence of spleen * Suffering from thrombocytopenia, bleeding disorders, or other coagulation disorders (which may cause contraindication to intramuscular injection) * Immunosuppressive therapy, anti-allergy therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, surface corticosteroids for acute uncomplicated dermatitis) within the past 6 months * Received blood products within 3 months prior to receiving the experimental drug * Participation in other studies involving interventional studies within 1 month prior to receiving the investigational drug and/or during the study participation period * Having received an injectable live attenuated vaccine within 14 days or another vaccine within 7 days prior to vaccination * In the judgment of the investigator, due to a variety of medical, psychological, social or other conditions that are contrary to the trial protocol or that affect the subject's ability to sign informed consent Exclusion criteria for subsequent doses * A vaccine-related serious adverse event occurred after the previous dose of vaccination * Who has experienced a Grade 3 or higher allergic reaction related to the vaccine after the previous dose of vaccination * Any other factors that, in the judgment of the investigator, make the subject unsuitable for continued participation in the clinical trial